Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001778 | 0.87 | KDM4E (0.54) | KDM4EPOLBGAARAB9ANPC1 | |
| SCHEMBL21014297 | 0.83 | KDM4E (0.50) | KDM4EPOLBUSP30GAARAB9A | |
| SCHEMBL21033166 | 0.83 | USP30 (0.55) | USP30EGLN1PIK3CGCLK1 | |
| SCHEMBL21033491 | 0.83 | KDM4E (0.55) | KDM4EPOLBUSP30GAARAB9A | |
| SCHEMBL21033938 | 0.83 | KDM4E (0.50) | KDM4EPOLBGAARAB9ANPC1 | |
| SCHEMBL21033937 | 0.82 | KDM4E (0.47) | KDM4EPOLBUSP30GAARAB9A | |
| SCHEMBL21033565 | 0.82 | KDM4E (0.57) | KDM4EPOLBGAARAB9ANPC1 | |
| SCHEMBL4083192 | 0.82 | KDM4E (0.60) | KDM4EPOLBGAARAB9ANPC1 | |
| SCHEMBL29908155 | 0.82 | USP30 (0.54) | USP30EGLN1PIK3CGCLK1 | |
| SCHEMBL24066046 | 0.82 | KDM4E (0.54) | KDM4EPOLBGAARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046512-A2 | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-03-07 | — | — | WO | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | JUBILANT EPISCRIBE LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 221/4885POLB 1269/4885USP30 1944/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM4E 221/4885POLB 1269/4885USP30 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.